• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is DENTSPLY SIRONA’s (XRAY) Steady Buyback and Reaffirmed Outlook Reframing Its Risk‑Reward Profile?

    Simply Wall St·08/13/2026 22:28:08
    Listen to the news
    • DENTSPLY SIRONA Inc. reported past second-quarter 2026 results showing sales of US$898 million, up from a net loss to net income of US$37 million, while reaffirming full-year 2026 net sales guidance of US$3.5 billion to US$3.6 billion.
    • Alongside this mix of lower year-on-year revenue and improved profitability, the company continued its long-running buyback, repurchasing 1,300,000 shares for US$12.92 million in the latest quarter.
    • We’ll now examine how reaffirmed full-year sales guidance below analyst expectations shapes DENTSPLY SIRONA’s existing investment narrative and risk-reward profile.

    AI is about to change healthcare. These 44 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

    DENTSPLY SIRONA Investment Narrative Recap

    To own DENTSPLY SIRONA, you need to believe its turnaround from inconsistent profits and soft elective demand can eventually support steadier growth from digital dentistry and international expansion. The latest quarter’s lower year-on-year sales but return to net income, alongside reaffirmed 2026 revenue guidance slightly below consensus, reinforces that the near term catalyst remains execution on this turnaround, while the biggest risk is that persistent revenue pressure in key categories limits any margin progress.

    The reaffirmed full year sales outlook of US$3.5 billion to US$3.6 billion is the most relevant update, because it anchors how much room the company has to invest behind its digital platforms and new distribution partnerships without stretching profitability. Against this, the ongoing share buyback, including the 1,300,000 shares repurchased for US$12.92 million in the quarter, gives existing shareholders a modest ownership boost but does not change the core execution risk.

    Yet beneath the improving profitability, investors should still be aware that...

    Read the full narrative on DENTSPLY SIRONA (it's free!)

    DENTSPLY SIRONA's narrative projects $3.8 billion revenue and $189.7 million earnings by 2029. This requires fairly flat yearly revenue growth and an $817.7 million earnings increase from -$628.0 million today.

    Uncover how DENTSPLY SIRONA's forecasts yield a $13.40 fair value, a 16% upside to its current price.

    Exploring Other Perspectives

    XRAY 1-Year Stock Price Chart
    XRAY 1-Year Stock Price Chart

    Some of the most optimistic analysts were assuming revenue around US$3.9 billion and earnings near US$373 million by 2029, which is a far stronger outcome than the more cautious views focused on slower DS Core monetization and ongoing cost pressures, so this new guidance and Q2 softness may prompt you to reassess which version of DENTSPLY SIRONA’s future you find more convincing.

    Explore 3 other fair value estimates on DENTSPLY SIRONA - why the stock might be worth just $13.40!

    Decide For Yourself

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    • A great starting point for your DENTSPLY SIRONA research is our analysis highlighting 3 key rewards that could impact your investment decision.
    • Our free DENTSPLY SIRONA research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate DENTSPLY SIRONA's overall financial health at a glance.

    Contemplating Other Strategies?

    These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.